KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer

nhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs (Balak et al., 2006; Kosaka et al., 2006; Rudin e...

Full description

Bibliographic Details
Main Authors: Krall, Elsa B (Author), Munoz, Diana M (Author), Ilic, Nina (Author), Niederst, Matthew J (Author), Yu, Kristine (Author), Ruddy, David A (Author), Redig, Amanda J (Author), Gainor, Justin F (Author), Williams, Juliet A (Author), Asara, John M (Author), Janne, Pasi A (Author), Shaw, Alice T (Author), McDonald III, Robert E (Author), Engelman, Jeffrey A (Author), Stegmeier, Frank (Author), Schlabach, Michael R (Author), Wang, Belinda (Contributor), Raghavan, Srivatsan (Contributor), Aguirre, Andrew J. (Contributor), Kim, Jong Wook (Contributor), Doench, John Gerard (Contributor), Hahn, William (Contributor)
Other Authors: Broad Institute of MIT and Harvard (Contributor)
Format: Article
Language:English
Published: eLife Sciences Publications, Ltd., 2017-06-14T19:44:49Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items